Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Arix Bioscience Plc LSE:ARIX London Ordinary Share GB00BD045071 ORD 0.001P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 178.00 36,154 08:00:00
Bid Price Offer Price High Price Low Price Open Price
177.00 179.00 178.00 178.00 178.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.48 126.30 96.60 1.8 237
Last Trade Time Trade Type Trade Size Trade Price Currency
15:32:53 O 2,637 178.98 GBX

Arix Bioscience (ARIX) Latest News (1)

Arix Bioscience News

Date Time Source Headline
14/6/202114:55UKREGResults of Annual General Meeting
11/6/202117:01UKREGTransaction in own shares
11/6/202113:05UKREGClinical portfolio update
10/6/202117:26UKREGTransaction in own shares
09/6/202117:15UKREGTransaction in own shares
08/6/202117:14UKREGTransaction in own shares
07/6/202117:08UKREGTransaction in own shares
04/6/202119:21ALNCIN BRIEF: Arix investee Harpoon presents updated data for HPN424
04/6/202117:13UKREGTransaction in own shares
04/6/202115:25UKREGHarpoon presents updated interim clinical data for HPN424 at the 2021 ASCO..
More Arix Bioscience News
Arix Bioscience Investors    Arix Bioscience Takeover Rumours

Arix Bioscience (ARIX) Discussions and Chat

Arix Bioscience Forums and Chat

Date Time Title Posts
11/6/202116:36Arix Bioscience plc307
30/7/201811:14Arix Bioscience (ARIX) One to Watch -

Add a New Thread

Arix Bioscience (ARIX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
14:32:55178.982,6374,719.70O
13:14:17177.551,0181,807.46O
13:12:31178.981,1171,999.21O
12:41:26177.7511,25019,996.88O
12:27:57177.55200355.10O
View all Arix Bioscience trades in real-time

Arix Bioscience (ARIX) Top Chat Posts

DateSubject
14/6/2021
09:20
Arix Bioscience Daily Update: Arix Bioscience Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ARIX. The last closing price for Arix Bioscience was 178p.
Arix Bioscience Plc has a 4 week average price of 174.50p and a 12 week average price of 174.50p.
The 1 year high share price is 229p while the 1 year low share price is currently 73p.
There are currently 133,297,800 shares in issue and the average daily traded volume is 150,396 shares. The market capitalisation of Arix Bioscience Plc is £237,270,084.
06/5/2021
15:21
eaaxs06: Arix are leaving their buying late today, indeed only just over 50k of shares hsave been traded all day. In normal cicumstances, the prospect of a imminent 100k purchse after such a slow day would help the share price nicely, but alas, things never work out as expected with Arix. Good luck everyone, Sid.
14/4/2021
08:49
ayl30: ExtractArtios management played key roles in AstraZeneca's discovery of Lynparza, a treatment for advanced ovarian cancer, another reason why both Merck and Novartis are backing them. Moreover, the collaborations strongly suggest that Arix has backed another major winner for its shareholders, having previously realised US$185m (£139m) for its 6.8 per cent stake in Velos Bio, a company that was acquired by Merck for US$2.75bn at the end of 2020.Arix invested £13.8m for a 12.4 per cent fully diluted stake in Artios and the holding has a modest carrying value of £19m. However, investment bank Jefferies valued the Artios stake at £49m after the Merck announcement, but before news of the Novartis collaboration. Jefferies' NAV estimate of £339m (250p a share) includes cash of £185m (136p a share), so effectively Arix's investment portfolio of listed and unquoted companies is in the price for half book value. That's a harsh valuation given that Artios is only one of several portfolio companies that are approaching key milestones over the next 12 months.I suggested buying Arix shares, at 168p, in my market-beating 2021 Bargain Shares Portfolio, and the news from Artios adds further weight to the investment case. Buy.
09/4/2021
14:53
ohisay: https://www.investorschronicle.co.uk/ideas/2021/04/08/five-investment-company-bargains/ Artios Pharma, a company backed by venture capital company Arix Bioscience (ARIX:190p), has entered into a three-year research collaboration with drug giant Novartis to discover and validate next-generation DNA Damage Response (DDR) targets to enhance Novartis' Radioligand Therapies (RLT). Artios is a leading DDR company that is developing a pipeline of precision medicines for the treatment of cancer. ...Artios management played key roles in AstraZeneca’s discovery of Lynparza, a treatment for advanced ovarian cancer, another reason why both Merck and Novartis are backing them. Moreover, the collaborations strongly suggest that Arix has backed another major winner for its shareholders, having previously realised US$185m (£139m) for its 6.8 per cent stake in Velos Bio, a company that was acquired by Merck for US$2.75bn at the end of 2020. Arix invested £13.8m for a 12.4 per cent fully diluted stake in Artios and the holding has a modest carrying value of £19m. However, investment bank Jefferies valued the Artios stake at £49m after the Merck announcement, but before news of the Novartis collaboration. Jefferies' NAV estimate of £339m (250p a share) includes cash of £185m (136p a share), so effectively Arix’s investment portfolio of listed and unquoted companies is in the price for half book value. That’s a harsh valuation given that Artios is only one of several portfolio companies that are approaching key milestones over the next 12 months. https://www.fiercebiotech.com/biotech/novartis-taps-artios-for-targets-to-enhance-radioligand-drugs
23/3/2021
05:28
ohisay: For the sake of argument lets take current NAV as 250p per share (Jefferies est). ie Assume cash £190m /140p per share other assets £150m/110p per share. Shares in issue 135.6m Assume they spend £25m (max possible)on share buy back at say 205p per share average.Can't see them getting much lower than this TBH over the next few months. Shares bought back is then 12.2m. New position then . Cash 165m/134p per share Other assets 150m/121p per share Shares in issue 123.4m . New NAV 255p. The lower they can buy back the shares of course the higher the Nav as the fewer shares in issue . Ideally I guess they would like to buy around 185p.. buying around 13.5m shares (circa 10%) to get the maximum spend of £25m...(that's the new floor for me) Makes complete sense to do a buy back when the market is currently valuing the non cash assets (at say overall current 195p share price) at circa £75m cf £150m book value. ie the effective current discount is actually 50% excluding the cash. Thats the real point of the buyback...
23/3/2021
00:29
pinemartin9: So we purchased 73000 shares today at 193.4. That is £141k of the possible £25M spent! We will weaken the balance sheet by reducing our cash but the effect on the share price will be interesting! My only concern with shares held in Treasury is if they will be gifted to the execs further down the line... There now remain 135,536,653 shares in issue. If they spent the remaining allowance at 200p then they would get about 12.5M shares and reduce the shares in circulation by about 10%. Theoretically this would mean each share would be worth about 10% more than presently. So this buy back should be worth about an extra 20p on the share price. What am I missing? Would this then also reduce the discount to NAV. Anyone more financially savvy than me who could shed more light?
15/3/2021
11:29
ohisay: Here it is... https://www.investegate.co.uk/arix-bioscience-plc--arix-/eqs/share-buyback-programme-of-up-to--25-million/20210315070007EBEHF/ LONDON, 15 March 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces Board approval of a share buyback programme of up to £25 million. The share buyback programme will be limited to the lower of £25 million or 13,555,185 shares, in line with the general authority to repurchase shares, which was granted by shareholders at the most recent annual general meeting held on 4 June 2020. Further details of the share buyback programme will follow.
10/3/2021
04:05
rambutan2: I agree: Acacia Research Corporation, a 19.05% shareholder in Arix Bioscience plc (LSE: ARIX), sent a letter to the Arix Senior Independent Director on 9 March 2021. Acacia is urging the Arix Board to meet with its largest shareholder ahead of the start date of the recently appointed directors, currently scheduled for April 1, in order to allow for proper discourse on the multitude of shareholder concerns. Arix has a disappointing governance history with 18 different directors in just five years, lacks gender diversity on the Board, and received minimal shareholder approval at AGMs. The disruption at the Board level has led to the departure of key investment professionals. Acacia believes these issues must be addressed on an urgent basis due to the recent receipt of proceeds by a team that now lacks adequate investment professionals. In its letter, Acacia recommends Arix immediately commence a search for a replacement CEO, restructure the Board with individuals who possess the requisite experience and skills, and in particular, a demonstrated record of successful Board service at companies with sound and stable Board functioning, and hire an experienced team of life sciences investment professionals. No decisions should be made on a reinvestment of the VelosBio (or any other) proceeds until such strategy is implemented. https://investegate.co.uk/acacia-research-corp/rns/acacia-initiates-plan-to-improve-arix-governance/202103091743367082R/
09/2/2021
14:45
snappler: I hold Arix as well and looking for research about the other Neil Woodford backed biotech Investment Company, Malin Corp. The share price is EUR 6. i calculated the fair value around EUR 9, taking the recent share price performance of Immunocore and the sale of kymab into account. Do you know any interesting sites about malin?
03/12/2020
08:09
n0rbie: Great piece of research from last month that I missed: Arix Bioscience (ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through a combination of an expert investment team and portfolio diversification. Along with its 2020 interim results, management provided the market with some aspirational targets for the next three years, which would see the NAV double to ca.£500m. News that Merck & Co is to acquire portfolio company, VelosBio, for $2.75bn cash, giving ARIX >12x return on its investment, will help to smash these targets. Strategy: ARIX sources investments from an established network and a strong scientific reputation. The portfolio is diversified by therapeutic area, treatment modality, stage of discovery/development and geography to balance the risk-reward profile. Value is realised when ARIX successfully exits its investments. Acquisition of VelosBio: Major pharmaceutical company, Merck & Co (MRK), has announced the acquisition VelosBio for $2.75bn cash, to boost its position in oncology and provide it with another breakthrough technology in this field. The transaction, subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act, is expected to close by the end of 2020. Return on investment: VelosBio was introduced to ARIX by its strategic partner, Takeda Ventures. ARIX co-led the company’s Series A funding round in 2018, committing $11m/£8.6m, and made a further investment of $4.0m/£3.2m in VelosVio’s Series B in July 2020. ARIX is expecting to receive $185m/£142m for its stake, representing a 12.3x return. Market reaction: Although the market responded favourably to this news, with the shares rising 55%, this equates to an increase in market capitalisation of only £74m compared with the £121m valuation uplift from the VelosBio consideration, and has expanded the discount to NAV from 31% to 34%. This suggests that the shares have much further to go. Investment summary: The principal reason that ARIX has been trading on a discount to its NAV has been the “lack of a track record”. Management tried to allay the market’s concern with its interim results when it highlighted the portfolio’s IRR of 20% since inception and set itself some ambitious targets for the next three years. The trade sale of VelosBio means that these targets should be easily met and the market should be giving far more credit to the company. https://www.hardmanandco.com/research/corporate-research/hitting-the-jackpot/
20/2/2020
07:52
stevenb3: Iterium and LogicBio were both up 11% yesterday on NASDAQ. However, I don't expect this to follow through into the Arix share price.
Arix Bioscience share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
ARIX
Arix Biosc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210614 15:57:01